Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics for Healthy Subjects in the Phase Ⅰ Clinical Study

NCT02356419 is registered in ClinicalTrials.gov with Shenyang Sunshine Pharmaceutical Co., LTD. as lead sponsor.

NCT NCT02356419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02356419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics for Healthy Subjects in the Phase Ⅰ Clinical Study
Lead sponsor
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase
Phase 1
Overall status
Unknown status
Start date
September 30, 2014
Completion date
March 31, 2015
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic renal failure